PolyNovo Keeps Bull Despite Sales Slowdown -- Market Talk
Dow Jones2026/07/30 05:010501 GMT - PolyNovo keeps its bulls at Morgans despite the medical-device maker's 2H revenue slowdown. Maintaining a buy rating on the stock, the Australian broker's analysts tell clients in a note that, while sales disappointed, cash generation is strong. They think this indicates the wound-treatment specialist is in a good position to deliver material Ebitda growth in each of its next two fiscal years. Morgans analysts say they remain confident that revenue growth can return above-20% levels in fiscal 2027, pointing out that 15.5% U.S. sales growth in fiscal 2026 was said by management to reflect some seasonality and shifts in insurance reimbursements. Morgans cuts its target price by 5.1% to 1.48 Australian dollars. Shares are down 3.4% at A$0.85. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
July 30, 2026 01:01 ET (05:01 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Novo Resources FY26 H1 net loss narrows to C$3.93 million
Novo posts Q2 net loss of C$3.25 million as exploration spending rises, MD&A says
QIC-backed QCMF funds Aeon Metals’ Walford Creek project studies, drilling
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
